ARS Pharms Stock Price, News & Analysis

ARS Pharmaceuticals (NASDAQ: SPRY) has secured a substantial $250 million senior secured term loan facility from RA Capital Management and OMERS Life Sciences. The company has initially borrowed $100 million to accelerate the commercialization of neffy®, their needle-free epinephrine treatment for allergic reactions.

The loan facility includes favorable terms with an interest rate of SOFR plus 5.5% and interest-only payments until September 2030. The company has access to additional tranches: $25 million available within 6-12 months, another $25 million subject to achieving $100 million in U.S. revenue, and an uncommitted $100 million incremental term loan.

Market response to neffy® has been strong, with 93% of patients surveyed being "very likely to consider" the treatment and the prescriber base nearly doubling in four months. The company expects the funding to support operations through cash-flow breakeven while targeting the $2 billion annual U.S. epinephrine market.

ARS Pharmaceuticals (NASDAQ:SPRY) has received Japanese regulatory approval for neffy®, the first needle-free epinephrine nasal spray for emergency treatment of allergic reactions (anaphylaxis). The approval covers both 1mg and 2mg doses for adults and children weighing over 15kg.

Through a partnership with Alfresa Holdings, neffy is expected to launch in Japan by Q4 2025. The approval triggers a $2 million milestone payment to ARS Pharma. This breakthrough addresses a significant market need, as approximately 900,000 Japanese individuals are affected by food allergies, yet only 14% of anaphylaxis patients reported having an epinephrine auto-injector prescription.

The product features a 24-month shelf life and is already commercially available in the US and parts of Europe, with additional approvals expected in Canada, Australia, New Zealand, and China by early 2026.

ARS Pharmaceuticals (NASDAQ:SPRY) has reported compelling real-world evidence for its neffy® (epinephrine nasal spray) in treating anaphylaxis. The study, accepted for publication in the Annals of Allergy, Asthma and Immunology, demonstrated that 89.2% of 545 patients experiencing anaphylaxis during oral food challenges and allergen immunotherapy were successfully treated with a single dose of neffy.

This success rate closely mirrors the 88.9% efficacy rate historically reported for traditional epinephrine injections, suggesting clinical interchangeability between the two delivery methods. The findings build upon previous clinical evidence, including a Phase 3 study, and represent the first large-scale analysis of neffy's treatment outcomes in routine clinical practice.

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company focused on anaphylaxis prevention, announced its participation in two upcoming investor conferences. The company's leadership will present at the Cantor Global Healthcare Conference on September 3, 2025, at 3:55 p.m. ET in New York, and the Stifel Immunology and Inflammation Summit on September 15, 2025, at 12:00 p.m. ET virtually.

Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will represent the company. Live webcasts will be available on the company's website, with replays accessible for 30 days after each event.

ARS Pharmaceuticals (NASDAQ: SPRY) reported strong Q2 2025 financial results, highlighting significant growth for neffy®, their needle-free epinephrine nasal spray. The company achieved $15.7 million in total revenue, including $12.8 million from U.S. neffy sales. Key commercial milestones include 93% commercial coverage and a 180% increase in prescription volumes from Q1 to Q2 2025.

The company has expanded globally with EURneffy® approval in the UK and launch in Germany. Financial position remains strong with $240.1 million in cash and investments, supporting operations for at least three years despite a net loss of $44.9 million for the quarter. The company has initiated a Phase 2b trial for urticaria and expects additional regulatory approvals in Canada, Japan, Australia, and China by 2026.

ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on anaphylaxis prevention, will host a conference call and webcast to discuss its Q2 2025 financial results on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.

Participants can register for the event to receive dial-in information. The webcast and presentation slides will be accessible through the Events & Presentations page on the company's website, with a replay available for 30 days after the event.

ARS Pharmaceuticals (NASDAQ:SPRY) has achieved a significant milestone as the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved EURneffy, the first needle-free adrenaline nasal spray for emergency treatment of allergic reactions. The approval covers adults and children weighing over 30 kg.

The company's partnership with ALK-Abelló A/S includes a $145 million upfront payment and potential additional payments of up to $320 million in milestones, plus tiered double-digit royalties. The UK represents the largest market outside the US for adrenaline auto-injector sales. EURneffy's launch is expected in late Q3 2025.

The product offers advantages including temperature stability up to 50°C and longer shelf life compared to auto-injectors. Additional regulatory approvals are anticipated in Canada, Japan, and Australia by end of 2025, with China following in 2026.

ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis prevention, has announced its participation in three upcoming investor conferences in June 2025:

• William Blair 45th Annual Growth Stock Conference in Chicago on June 3, 2025 at 11:20 a.m. CT
• 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025 at 5:30 p.m. ET
• Scotiabank Third Annual Healthcare Canadian Investor Day in Toronto on June 17, 2025

Company executives Richard Lowenthal (Co-Founder, President and CEO) and Eric Karas (Chief Commercial Officer) will lead presentations at the William Blair and Jefferies conferences. Live and archived webcasts will be available on the company's website for 30 days following each event.

ARS Pharmaceuticals (NASDAQ: SPRY) reported Q1 2025 financial results and progress in the U.S. launch of neffy®, their FDA-approved needle-free epinephrine nasal spray. The company achieved $7.8 million in neffy U.S. net product revenue. Key highlights include: nationwide availability of neffy 1mg for children aged 4+ and 2mg for adults, co-promotion agreement with ALK-Abelló reaching nearly 20,000 healthcare providers, and over 5,000 prescribing physicians to date. Financial results show $275.7 million in cash reserves with runway for 3+ years, though the company reported a net loss of $33.9 million. Commercial progress includes 57% commercial coverage, with United Healthcare added April 1st, and over 1,000 schools enrolled in the neffyinSchools program. The company plans to launch a comprehensive DTC marketing campaign and expects regulatory decisions in multiple international markets throughout 2025-2026.